首页> 外文OA文献 >Baroreflex Activation Therapy for the Treatment of Drug-Resistant Hypertension: New Developments
【2h】

Baroreflex Activation Therapy for the Treatment of Drug-Resistant Hypertension: New Developments

机译:压力反射激活疗法治疗抗药性高血压:新进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In the past few years, novel accomplishments have been obtained in carotid baroreflex activation therapy (BAT) for the treatment of resistant hypertension. In addition, this field is still evolving with promising results in the reduction of blood pressure and heart rate. This overview addresses the latest developments in BAT for the treatment of drug-resistant hypertension. Although not totally understood considering the working mechanisms of BAT, it appeared to be possible to achieve at least as much efficacy of single-sided as bilateral stimulation. Therefore unlike the first-generation Rheos system, the second-generation Barostim neo operates by unilateral baroreflex activation, using a completely different carotid electrode. Also significant improvements in several cardiac parameters have been shown by BAT in hypertensive patients, which set the basis for further research to evaluate BAT as a therapy for systolic heart failure. Yet important uncertainties need to be clarified to guarantee beneficial effects; hence not all participants seem to respond to BAT.
机译:在过去的几年中,在颈动脉压力反射激活疗法(BAT)中治疗耐药性高血压取得了新的成就。另外,该领域仍在发展,其在降低血压和心率方面具有可喜的结果。本概述介绍了BAT在抗药性高血压治疗中的最新进展。尽管考虑BAT的工作机制尚不完全了解,但似乎有可能至少获得与双侧刺激一样高的单侧疗效。因此,与第一代Rheos系统不同,第二代Barostim neo使用完全不同的颈动脉电极通过单侧压力反射激活来进行操作。 BAT在高血压患者中也显示出一些心脏参数的显着改善,这为进一步评估BAT作为收缩期心力衰竭的治疗奠定了基础。然而,需要澄清重要的不确定因素以保证有益的效果。因此,并非所有参与者似乎都对BAT做出回应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号